Emboline, Inc.
- Industry
- Medical Devices & Equipment
- Founded Year
- 2011
- Headquarters
- 2811 Mission St, Santa Cruz, California, 95060, United States
- Employee Count
- 21
Key People
- Scott Russell - President and Chief Executive Officer
- Amir Belson - Founder and Chief Technology Officer
- Stephen Kleshinski - Vice President of Research and Development
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology.
The leadership team includes individuals with proven track records in the MedTech industry, such as Amir Belson, who has founded multiple successful medical device companies. This depth of experience positions Emboline favorably in the market.
- Clinical Need
-
Aspect: Very Strong
Summary: Emboline addresses a critical need for embolic protection during transcatheter heart procedures.
Transcatheter heart procedures carry risks of embolic events leading to strokes and other complications. Emboline's Emboliner device offers comprehensive embolic protection, addressing a vital need in cardiovascular interventions.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing competitors, but Emboline offers a differentiated solution.
The embolic protection device market includes several players; however, Emboline's Emboliner offers total embolic protection, potentially setting it apart from partial protection solutions.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and validating the Emboliner involves moderate technical challenges.
The development of the Emboliner requires addressing challenges related to device deployment, compatibility with existing procedures, and ensuring comprehensive embolic protection. The team's experience mitigates these challenges.
- Patent
-
Aspect: Strong
Summary: Emboline holds strong patents for its embolic protection technology.
Emboline has been granted patents for integrated embolic protection devices, reinforcing its position in the market and protecting its innovative solutions.
- Financing
-
Aspect: Well-funded
Summary: Emboline has secured substantial funding to support its development and commercialization efforts.
With over $80 million raised across multiple funding rounds, including a $55 million Series D in 2021, Emboline is well-positioned to advance its product development and market entry strategies.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Emboline is progressing through pivotal trials to obtain regulatory approvals.
Emboline has completed clinical studies demonstrating the efficacy of the Emboliner and is working towards obtaining CE Mark and FDA approvals to commercialize the device in key markets.
Opportunity Rollup
- Odds of Success
- 3.55
- Peak Market Share
- 4.4
- Segment CAGR
- 4.4%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Embolic Protection Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
Emboline's innovative embolic protection device addresses a critical need in cardiovascular procedures, supported by a strong team and substantial funding, positioning the company for significant market impact.